Geneos Therapeutics, a Plymouth Meeting, PA-based clinical stage biotherapeutics company, raised $5M in Series A 3 funding.
The round, which brought the total amount to $10M, saw participation form Shanghai Healthcare Capital. Dr. Jing Bao, partner of SHC, will join as a board observer, bringing extensive expertise in the pharmaceutical industry and with global clinical trials.
Led by Niranjan Sardesai, PhD., President and CEO, Geneos Therapeutics is a clinical stage biotherapeutics company providing personalized therapeutic cancer vaccines (PTCVs). Its approach, using its proprietary GT-EPIC™ platform, is to target neoantigens (abnormal mutations produced by cancer cells) from individual patient tumors to develop personalized treatments for cancer.
The company intends to use the funds to accelerate the Phase 1b/2a GT-30 Program.
GT-30 is evaluating the safety, and efficacy of PTCV (GNOS-PV02 plus plasmid-encoded IL-12) administered in combination with the immune checkpoint inhibitor pembrolizumab, in 36 patients with unresectable or metastatic hepatocellular carcinoma (HCC) who progress on, or are intolerant to, first-line tyrosine kinase inhibitors (sorafenib or lenvatinib). Study enrollment completed in June of this year with the top-line safety and clinical response data from the complete cohort of 36 patients is anticipated by the end of the year.
FinSMEs
28/09/2023